Organon & Co. (NYSE:OGN) Receives Average Rating of “Hold” from Analysts

Organon & Co. (NYSE:OGN) has earned a consensus rating of “Hold” from the seven analysts that are presently covering the firm, MarketBeat reports. One investment analyst has rated the stock with a sell recommendation, three have given a hold recommendation, two have assigned a buy recommendation and one has given a strong buy recommendation to the company. The average 1-year price objective among analysts that have issued a report on the stock in the last year is $20.80.

A number of analysts have recently commented on the company. Morgan Stanley lowered their target price on Organon & Co. from $17.00 to $16.00 and set an “equal weight” rating on the stock in a research note on Friday, February 14th. TD Cowen raised shares of Organon & Co. to a “hold” rating in a research note on Wednesday, January 15th. Finally, Barclays decreased their target price on shares of Organon & Co. from $26.00 to $24.00 and set an “overweight” rating for the company in a research note on Friday, February 14th.

Organon & Co. Stock Performance

OGN opened at $15.69 on Friday. The company has a market cap of $4.04 billion, a P/E ratio of 4.71, a price-to-earnings-growth ratio of 0.86 and a beta of 0.76. The company has a quick ratio of 1.21, a current ratio of 1.70 and a debt-to-equity ratio of 17.73. The firm’s 50-day moving average price is $15.36 and its 200-day moving average price is $17.31. Organon & Co. has a 52-week low of $13.87 and a 52-week high of $23.10.

Organon & Co. (NYSE:OGN) last issued its quarterly earnings results on Thursday, February 13th. The company reported $0.83 EPS for the quarter, missing analysts’ consensus estimates of $0.92 by ($0.09). Organon & Co. had a return on equity of 431.62% and a net margin of 13.49%. The firm had revenue of $1.59 billion for the quarter, compared to analyst estimates of $1.57 billion. As a group, equities analysts anticipate that Organon & Co. will post 3.78 EPS for the current fiscal year.

Organon & Co. Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Thursday, March 13th. Shareholders of record on Monday, February 24th will be given a $0.28 dividend. The ex-dividend date of this dividend is Monday, February 24th. This represents a $1.12 dividend on an annualized basis and a yield of 7.14%. Organon & Co.’s dividend payout ratio is currently 33.63%.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the stock. Barclays PLC lifted its stake in Organon & Co. by 238.0% during the third quarter. Barclays PLC now owns 119,483 shares of the company’s stock worth $2,285,000 after purchasing an additional 84,136 shares in the last quarter. Weiss Asset Management LP purchased a new stake in shares of Organon & Co. in the 3rd quarter valued at $32,966,000. Cerity Partners LLC lifted its stake in Organon & Co. by 94.0% during the 3rd quarter. Cerity Partners LLC now owns 667,340 shares of the company’s stock worth $12,766,000 after acquiring an additional 323,308 shares in the last quarter. Foundry Partners LLC purchased a new position in Organon & Co. during the 3rd quarter valued at about $7,642,000. Finally, Beddow Capital Management Inc. boosted its holdings in Organon & Co. by 38.8% during the 3rd quarter. Beddow Capital Management Inc. now owns 306,675 shares of the company’s stock valued at $5,867,000 after acquiring an additional 85,775 shares during the period. Institutional investors and hedge funds own 77.43% of the company’s stock.

Organon & Co. Company Profile

Organon & Co is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.